Retrospective observational study on the effect of the use of SGLT2 inhibitors in the treatment of Type I Diabetes Mellitus

Type I diabetes is one of the most relevant metabolic diseases today, both worldwide and in our environment. Its treatment has historically been based on the administration of insulin and, although this is still the case, new alternatives are transforming or adding to this treatment. This study aims to compare the effects of treatment with multiple insulin injections plus Dapagliflozin (SGLT2 inhibitor) with those of treatment with a Continuous Insulin Infusion Pump. Such effects include their effectiveness and efficiency in lowering HbA1c levels, as well as promoting weight loss and glycemic control (HbA1c<7%). For this purpose, data in this regard were extracted from patients' medical records, and subjected to statistical analysis. The costs of each treatment were also calculated. In addition, the possible adverse effects were observed and collected. It was concluded that treatment with Dapagliflozin was more efficient and perhaps more effective in lowering HbA1c. It was also the only treatment shown to contribute significantly to weight loss. On the other hand, no significant adverse effects were reported in either group. These results could be of particular relevance after the withdrawal of the indication of Dapagliflozin for the treatment of IMD. ; La Diabetes tipo I es una de las enfermedades metabólicas más relevantes a día de hoy, tanto a nivel mundial como en nuestro medio. Su tratamiento ha estado históricamente basado en la administración de insulina y, aunque sigue siendo así, nuevas alternativas están transformando o sumándose a dicho tratamiento. Este estudio pretende comparar los efectos del tratamiento mediante múltiples inyecciones de insulina sumadas a Dapagliflozina (ISGLT2) con los del tratamiento con Bomba de Infusión Continua de Insulina. Dichos efectos incluyen su efectividad y eficiencia a la hora de disminuir los niveles de HbA1c, así como de promover la pérdida de peso y el control glucémico (HbA1c<7%). Para ello, se extrajeron los datos a este respecto de las historias clínicas ...